AZTREONAM FOR INHALATION SOLUTION (AZLI) TREATMENT IN CHILDREN WITH CYSTIC FIBROSIS (CF) AND CHRONIC PSEUDOMONAS AERUGINOSA (PA) INFECTION

被引：0
|
作者：
Accurso, F. J. [1 ]
Fayon, M. [2 ]
Sermet, I. [3 ]
Lewis, S. [4 ]
Bresnik, M. [5 ]
Oermann, C. M. [6 ]
机构：
[1] UCD Childrens Hosp Colorado, Dept Pediat, Aurora, CO USA
[2] CHU Bordeaux, CIC 0005, Bordeaux, France
[3] Hop Necker Enfants Malad, CHU Paris, Paris, France
[4] Gilead Sci Inc, Seattle, WA USA
[5] Gilead Sci Inc, Foster City, CA 94404 USA
[6] Baylor Coll Med, Houston, TX 77030 USA
来源：
PEDIATRIC PULMONOLOGY | 2013年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：343 / 343
页数：1
相关论文
共 50 条
  • [31] Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection
    Elborn, J. Stuart
    Flume, Patrick A.
    Cohen, Fredric
    Loutit, Jeffery
    VanDevanter, Donald R.
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2016, 15 (05) : 634 - 640
  • [32] LONG-TERM STUDY OF LIPOSOMAL AMIKACIN FOR INHALATION (LAI) IN PATIENTS WITH CYSTIC FIBROSIS (CF) AND CHRONIC PSEUDOMONAS AERUGINOSA INFECTION
    Konstan, M.
    Fajac, I
    Pressler, T.
    Clancy, J. P.
    Sands, D.
    Minic, P.
    Cipolli, M.
    Galeva, I
    Sole, A.
    Monroe, R.
    McGinnis, J. P., II
    Eagle, G.
    Bilton, D.
    [J]. PEDIATRIC PULMONOLOGY, 2015, 50 : 270 - 270
  • [33] Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis
    Lam, John
    Vaughan, Steven
    Parkins, Michael D.
    [J]. CLINICAL MEDICINE INSIGHTS-CIRCULATORY RESPIRATORY AND PULMONARY MEDICINE, 2013, 7 : 61 - 77
  • [34] Tobramycin Inhalation Powder: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
    McKeage, Kate
    [J]. DRUGS, 2013, 73 (16) : 1815 - 1827
  • [35] Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
    Srilekha Panguluri
    Praveen Gunda
    Laurie Debonnett
    Kamal Hamed
    [J]. Clinical Drug Investigation, 2017, 37 : 795 - 805
  • [36] Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
    Panguluri, Srilekha
    Gunda, Praveen
    Debonnett, Laurie
    Hamed, Kamal
    [J]. CLINICAL DRUG INVESTIGATION, 2017, 37 (08) : 795 - 805
  • [37] Tobramycin Inhalation Powder: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
    Kate McKeage
    [J]. Drugs, 2013, 73 : 1815 - 1827
  • [38] Phase 3 trial (air-CF 1) measuring improvement in respiratory symptoms in patients with cystic fibrosis (CF) following treatment with aztreonam lysine for inhalation (AZLI)
    Retsch-Bogart, G. Z.
    Montgomery, B.
    Gibson, R.
    McCoy, K.
    Oermann, C. M.
    Cooper, P.
    [J]. PEDIATRIC PULMONOLOGY, 2007, : 310 - 311
  • [39] Defining chronic Pseudomonas aeruginosa infection in cystic fibrosis
    Waters, Valerie
    Grimwood, Keith
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2018, 17 (03) : 292 - 293
  • [40] Prevention of chronic infection with Pseudomonas aeruginosa infection in cystic fibrosis
    Zemanick, Edith T.
    Bell, Scott C.
    [J]. CURRENT OPINION IN PULMONARY MEDICINE, 2019, 25 (06) : 636 - 645
12345